MD Anderson, Cellectis enter CAR T collaboration

The University of Texas MD Anderson Cancer Center (Houston, Texas) and Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) entered a seven-year collaboration to co-develop four allogeneic chimeric antigen receptor T cell therapies from Cellectis to treat liquid tumors. Cellectis' candidates are expected to enter clinical testing within the next 12 months.

The partners will develop UCARTCS1, UCART22 and UCART38 to treat T cell acute lymphocytic leukemia (ALL). UCARTCS1 targets SLAM family member 7 ( SLAMF7; CS1), UCART22 targets CD22 and UCART38 targets CD38. ...